Genasense oblimersen regulatory update

FDA accepted for filing an NDA for Genasense oblimersen for use in combination with chemotherapy to treat relapsed or refractory chronic lymphocytic leukemia (CLL). The PDUFA date is Oct. 28. An MAA f...